Delivery of the Sox9 gene promotes chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells in an in vitro model

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 4, 2014, Pages 279-286

  Wang, Z H ^a   Li, X L ^a   He, X J ^a   Wu, B J ^a   Xu, M ^a   Chang, H M ^b   Zhang, X H ^a   Xing, Z ^c   Jing, X H ^a   Kong, D M ^a   Kou, X H ^a   Yang, Y Y ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b XI'AN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Chondrogenesis; Genetic modification; Sox9; Stem cells; Tissue engineering

Indexed keywords

ACTIN; AGGRECAN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; PROTEOGLYCAN; GREEN FLUORESCENT PROTEIN; SOX9 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX9;

ARTICLE; CARTILAGE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION ASSAY; CELL STRUCTURE; CHONDROGENESIS; CONTROLLED STUDY; FIBROBLAST; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NEWBORN; PLASMID; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SRY RELATED HIGH MOBILITY GROUP BOX 9 GENE; UMBILICAL CORD BLOOD; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; FETUS BLOOD; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE; TISSUE ENGINEERING; UMBILICAL VEIN ENDOTHELIAL CELL;

AGGRECANS; BLOTTING, WESTERN; CARTILAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROCYTES; CHONDROGENESIS; COLLAGEN TYPE II; FETAL BLOOD; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; PRIMARY CELL CULTURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOX9 TRANSCRIPTION FACTOR; TISSUE ENGINEERING; TRANSFECTION;

EID: 84898905285     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133539     Document Type: Article

References (33)

1. Redman SN, Oldfield SF, Archer CW. Current strategies for articular cartilage repair. Eur Cell Mater 2005; 9: 23-32.
2. Popa E, Reis R, Gomes M. Chondrogenic phenotype of different cells encapsulated in kappa-carrageenan hydrogels for cartilage regeneration strategies. Biotechnol Appl Biochem 2012; 59: 132-141, doi: 10.1002/bab.1007.
3. Oldershaw RA. Cell sources for the regeneration of articular cartilage: the past, the horizon and the future. Int J Exp Pathol 2012; 93: 389-400.
4. Schulze-Tanzil G. Activation and dedifferentiation of chondrocytes: implications in cartilage injury and repair. Ann Anat 2009; 191: 325-338, doi: 10.1016/j.aanat.2009.05.003.
5. Kock L, van Donkelaar CC, Ito K. Tissue engineering of functional articular cartilage: the current status. Cell Tissue Res 2012; 347: 613-627, doi: 10.1007/s00441-011-1243-1.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147, doi: 10.1126/science.284.5411.143.
7. Qian Q, Qian H, Zhang X, Zhu W, Yan Y, Ye S, et al. 5- Azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase. Stem Cells Dev 2012; 21: 67-75, doi: 10.1089/scd.2010.0519.
8. Yuan J, Huang G, Xiao Z, Lin L, Han T. Overexpression of beta-NGF promotes differentiation of bone marrow mesenchymal stem cells into neurons through regulation of AKT and MAPK pathway. Mol Cell Biochem 2013; 383: 201-211, doi: 10.1007/s11010-013-1768-6.
9. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011; 109: 923-940, doi: 10.1161/CIRCRESAHA.111.243147.
10. Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M, et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant 2011; 20: 1395-1408, doi: 10.3727/096368910X557245.
11. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008; 111: 430-438, doi: 10.1182/blood-2007-03- 078774.
12. Elsler S, Schetting S, Schmitt G, Kohn D, Madry H, Cucchiarini M. Effective, safe nonviral gene transfer to preserve the chondrogenic differentiation potential of human mesenchymal stem cells. J Gene Med 2012; 14: 501-511, doi: 10.1002/jgm.2644.
13. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999; 22: 85-89, doi: 10.1038/8792.
14. Cucchiarini M, Thurn T, Weimer A, Kohn D, Terwilliger EF, Madry H. Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. Arthritis Rheum 2007; 56: 158-167, doi: 10.1002/art.22299.
15. Kawakami Y, Tsuda M, Takahashi S, Taniguchi N, Esteban CR, Zemmyo M, et al. Transcriptional coactivator PGC-1 alpha regulates chondrogenesis via association with Sox9. Proc Natl Acad Sci U S A 2005; 102: 2414-2419, doi: 10.1073/ pnas.0407510102.
16. Venkatesan JK, Ekici M, Madry H, Schmitt G, Kohn D, Cucchiarini M. SOX9 gene transfer via safe, stable, replication-defective recombinant adeno-associated virus vectors as a novel, powerful tool to enhance the chondrogenic potential of human mesenchymal stem cells. Stem Cell Res Ther 2012; 3: 22, doi: 10.1186/scrt113.
17. Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013; 14: 17986-18001, doi: 10.3390/ijms140917986.
18. Yao TH, Yang ZQ, Wang ZH, Tu JB, Ma JM. Inducing differentiation of human umbilical cord blood mesenchymal stem cells into chondroblast in vitro. Chin J Aesth Med 2007; 16: 450-454.
19. Wang ZH, Yang ZQ, He XJ, Kamal BE, Xing Z. Lentivirusmediated knockdown of aggrecanase-1 and -2 promotes chondrocyte-engineered cartilage formation in vitro. Biotechnol Bioeng 2010; 107: 730-736, doi: 10.1002/bit. 22862.
20. Wang ZH, Yang ZQ, He XJ, Wang L, Li LX, Tu JB. Effects of RNAi-mediated inhibition of aggrecanase-1 and aggrecanase- 2 on rat costochondral chondrocytes in vitro. Acta Pharmacol Sin 2008; 29: 1215-1226, doi: 10.1111/j.1745-7254.2008.00856.x.
21. Jung S, Panchalingam KM, Wuerth RD, Rosenberg L, Behie LA. Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem 2012; 59: 106-120, doi: 10.1002/bab.1006.
22. Wlodarski KH, Wlodarski P, Galus R, Mazur S. Adipose mesenchymal stem cells. Their characteristics and potential application in tissue repair. Pol Orthop Traumatol 2012; 77: 97-99.
23. Patel AN, Vargas V, Revello P, Bull DA. Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue. Cell Transplant 2013; 22: 513-519, doi: 10.3727/096368912X655064.
24. Choudhery MS, Badowski M, Muise A, Harris DT. Comparison of human mesenchymal stem cells derived from adipose and cord tissue. Cytotherapy 2013; 15: 330-343, doi: 10.1016/j.jcyt.2012.11.010.
25. Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, et al. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev 2008; 17: 761-773, doi: 10.1089/scd.2007.0217.
26. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301, doi: 10.1634/stemcells.2005- 0342.
27. Steinert AF, Palmer GD, Pilapil C, Noth U, Evans CH, Ghivizzani SC. Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. Tissue Eng Part A 2009; 15: 1127-1139, doi: 10.1089/ten.tea. 2007.0252.
28. Steinert AF, Proffen B, Kunz M, Hendrich C, Ghivizzani SC, Noth U, et al. Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Res Ther 2009; 11: R148, doi: 10.1186/ar2822.
29. Kawamura K, Chu CR, Sobajima S, Robbins PD, Fu FH, Izzo NJ, et al. Adenoviral-mediated transfer of TGF-beta1 but not IGF-1 induces chondrogenic differentiation of human mesenchymal stem cells in pellet cultures. Exp Hematol 2005; 33: 865-872, doi: 10.1016/j.exphem.2005.05.010.
30. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 2005; 280: 8343-8350, doi: 10.1074/jbc.M41391 3200.
31. Chang Y, Ueng SW, Lin-Chao S, Chao CC. Involvement of Gas7 along the ERK1/2 MAP kinase and SOX9 pathway in chondrogenesis of human marrow-derived mesenchymal stem cells. Osteoarthritis Cartilage 2008; 16: 1403-1412, doi: 10.1016/j.joca.2008.03.018.
32. Galotto M, Campanile G, Robino G, Cancedda FD, Bianco P, Cancedda R. Hypertrophic chondrocytes undergo further differentiation to osteoblast-like cells and participate in the initial bone formation in developing chick embryo. J Bone Miner Res 1994; 9: 1239-1249, doi: 10.1002/jbmr. 5650090814.
33. Ikegami D, Akiyama H, Suzuki A, Nakamura T, Nakano T, Yoshikawa H, et al. Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development 2011; 138: 1507-1519, doi: 10.1242/ dev.057802.